<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501680</url>
  </required_header>
  <id_info>
    <org_study_id>HAPinsulin</org_study_id>
    <nct_id>NCT03501680</nct_id>
  </id_info>
  <brief_title>Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.</brief_title>
  <acronym>HAPinsulin</acronym>
  <official_title>Randomized, Controlled, Open-label Trial of Intravenous Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the therapeutic efficacy of intensive insulin in&#xD;
      patients with hypertriglyceridemia induced moderate/severe acute pancreatitis on the course&#xD;
      and outcome of disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertriglyceridemia-induced acute pancreatitis occurs in about 1-4% of the cases. It is the&#xD;
      third leading cause of pancreatitis after biliary and alcoholic etiology.&#xD;
      Hypertriglyceridemia can be caused by primary causes, lipid metabolism disorders and&#xD;
      secondary causes.&#xD;
&#xD;
      Hyperlipidemic pancreatitis can be provoked when triglyceride levels (TGL) exceed 11.3 mmol/l&#xD;
      (1,000 mg/dl). Except for standard symptomatic treatment, plasmapheresis and insulin have&#xD;
      been performed to rapidly reduce TGL and chylomicron levels in the blood.The therapeutic&#xD;
      efficacy of intensive insulin, standard insulin, and plasmapheresis in patients with&#xD;
      hypertriglyceridemia induced moderate/severe acute pancreatitis on the course and outcome of&#xD;
      disease.After acceptance patients will be randomized by random envelope in the 3 groups:&#xD;
      Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin&#xD;
      (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of mortality</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>Number of participants with fatal outcome during hospitalisation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of organ failure</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>reanl failure, respiratory failure, circulatory failure etal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>triglyceride levels</measure>
    <time_frame>From admition to hospital discharge, an average of 2 months</time_frame>
    <description>triglyceride levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokines in serum, urine</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>IL-6, IL-8, IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Score in CT scan</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>CT Balthazar score/grade or MCTSI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α in serum, urine</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>BISAP score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Genomics</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>cfDNA et.al.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>Ranson score</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>From admition to 7 days</time_frame>
    <description>Apache2</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Group A: intensive insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: standard insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: plasmapheresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: plasmapheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.&#xD;
Insulin was injected by insulin pump.</description>
    <arm_group_label>Group A: intensive insulin</arm_group_label>
    <arm_group_label>Group B: standard insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>plasmapheresis</intervention_name>
    <description>Triglyceridemia should be less than 5.65 mmol/l.</description>
    <arm_group_label>Group C: plasmapheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of hypertriglyceridemia induced acute pancreatitis (AP): Typical pain&#xD;
             increase in serum lipase or amylase with serum TG&gt; 1,000 mg/dL (11.3mmol/L) or serum&#xD;
             was milky with serum TG&gt; 500 mg/dL(5.65 mmol/L)&#xD;
&#xD;
          -  Onset of abdominal pain within &lt;=48h before admission&#xD;
&#xD;
          -  moderate severe or severe Acute Pancreatitis according to Atlanta criteria&#xD;
&#xD;
          -  except for other AP causes, such as cholelithiasis, alcohol, drugs and so on&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other etiologies other than hyperlipidemia leading to AP&#xD;
&#xD;
          -  at the same time combined with other etiologies of AP&#xD;
&#xD;
          -  appear difficult to reverse respiratory failure, severe systemic circulatory failure,&#xD;
             coma and other the endangered symptoms, patients expected to die within 24hours&#xD;
&#xD;
          -  disseminated intravascular coagulation, or patients with severe active bleeding&#xD;
&#xD;
          -  without informed consent, the patient refused to plasma replacement, and other&#xD;
             circumstances may bring significant bias.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng-Tao Zhou, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KeQing Shi, M.D.</last_name>
    <phone>(086)15858515296</phone>
    <email>skochilly@163.com</email>
  </overall_contact>
  <reference>
    <citation>Lutfi R, Huang J, Wong HR. Plasmapheresis to treat hypertriglyceridemia in a child with diabetic ketoacidosis and pancreatitis. Pediatrics. 2012 Jan;129(1):e195-8. doi: 10.1542/peds.2011-0217. Epub 2011 Dec 26.</citation>
    <PMID>22201145</PMID>
  </reference>
  <reference>
    <citation>Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009 Apr;104(4):984-91. doi: 10.1038/ajg.2009.27. Epub 2009 Mar 17. Review.</citation>
    <PMID>19293788</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Meng-Tao Zhou</investigator_full_name>
    <investigator_title>The director of the department of pancreatitis; the president of First Affiliated Hospital of Wenzhou Medical Univeristy</investigator_title>
  </responsible_party>
  <keyword>hyperlipidaemic pancreatitis</keyword>
  <keyword>Plasmapheresis</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

